<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797757</url>
  </required_header>
  <id_info>
    <org_study_id>10.29.NRC</org_study_id>
    <nct_id>NCT01797757</nct_id>
  </id_info>
  <brief_title>Comparison of MAG and Fish Oil Efficacy</brief_title>
  <official_title>Comparison of the Efficacy of Monoacylglycerol (MAG) and Triacylglycerol (TAG) to Deliver Long Chain Polyunsaturated Fatty Acids (LC-PUFA) Under Malabsorption Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A potential application for unstructured monoacylglycerol (MAG) containing long chain&#xD;
      polyunsaturated fatty acids (LC-PUFA)can be to provide essential fatty acids to humans who&#xD;
      chronically consume lipases inhibitor such as Orlistat® for weigh lowering reasons. Indeed,&#xD;
      it is predictable that chronic consumption of Orlistat® led to a depletion of essential fatty&#xD;
      acids with time, therefore unstructured MAG containing LC-PUFA can be an option as a source&#xD;
      of LC-PUFA for patients under Orlistat® treatment and hypothetically for subjects with other&#xD;
      type of maldigestion/malabsorption. Potential applications of such concept are therefore&#xD;
      related to disease conditions comprising low lipid digestion due to lipase activity&#xD;
      insufficiency.&#xD;
&#xD;
      In the present study, in order to see the response information for eicosapentanoic acid (EPA)&#xD;
      delivery, EPA will be provided either as a mixture of free monoacylglycerols or as&#xD;
      triacylglycerol (TAG). The erythrocyte and plasma fatty acid composition from subjects under&#xD;
      Orlistat® consumption will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be accretion of EPA in erythrocytes at 21days</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• The secondary outcome will be the incorporation of EPA in plasma + chylomicrons</measure>
    <time_frame>from baseline to day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Fish oil enriched with EPA + ORLISTAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.&#xD;
The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAG-EPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAG-EPA + ORLISTAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.&#xD;
The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil enriched with EPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil enriched with EPA</intervention_name>
    <arm_group_label>Fish oil enriched with EPA</arm_group_label>
    <arm_group_label>Fish oil enriched with EPA + ORLISTAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MAG-EPA oil</intervention_name>
    <arm_group_label>MAG-EPA</arm_group_label>
    <arm_group_label>MAG-EPA + ORLISTAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <arm_group_label>Fish oil enriched with EPA + ORLISTAT</arm_group_label>
    <arm_group_label>MAG-EPA + ORLISTAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Sex female&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 30kg/m2 and &lt; 40kg/m2&#xD;
&#xD;
          -  Subjects willing to undergo treatment with Orlistat® (Xenical).&#xD;
&#xD;
          -  Having obtained her written informed consent before any study related procedure&#xD;
             including the pre-inclusion period.&#xD;
&#xD;
        Subject exclusion criteria:&#xD;
&#xD;
          -  Binge eating disorder&#xD;
&#xD;
          -  Any other weight loss treatment(s) within the last 3 months&#xD;
&#xD;
          -  Vegetarians&#xD;
&#xD;
          -  History of metabolic, cardiovascular, hepatic or renal diseases&#xD;
&#xD;
          -  Obstructed bile duct&#xD;
&#xD;
          -  Diseases that could interfere with intestinal absorption History of abdominal /&#xD;
             gastric surgery (except appendicectomy)&#xD;
&#xD;
          -  Use of drugs or illicit substances&#xD;
&#xD;
          -  Consumption of alcohol &gt; 50 gr/week&#xD;
&#xD;
          -  Any other clinically significant abnormalities on screening laboratory evaluation&#xD;
             (creatinine, Na, K, urique acide, ASAT, ALAT, Ph. Alc., yGT, Glycemia, total&#xD;
             cholesterol, HDL, LDL, triglycerides) concentrations &gt; 2.5 fold normal range&#xD;
&#xD;
          -  Pregnant or lactating mothers&#xD;
&#xD;
          -  Allergy to fish oil or other components (for e.g., gelatin or excepients of the&#xD;
             capsule)&#xD;
&#xD;
          -  Use of any other supplements containing fish oil for the duration of the trial or 3&#xD;
             month before inclusion in trial.&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Having donated blood or had a transfusion of blood/blood products during the trial and&#xD;
             3 months prior to screening or expected to do so during the study&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Subject who cannot be expected to comply with the study procedures.&#xD;
&#xD;
          -  Currently participating or having participated in another clinical trial during last 8&#xD;
             weeks prior to the beginning of this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vittorio Giusti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EPA</keyword>
  <keyword>LC-PUFA</keyword>
  <keyword>Orlistat</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

